AR080662A1 - Forma de dosis oral solida con contenido de nanoparticulas y proceso de formulacion de la misma utilizando gelatina de pescado - Google Patents

Forma de dosis oral solida con contenido de nanoparticulas y proceso de formulacion de la misma utilizando gelatina de pescado

Info

Publication number
AR080662A1
AR080662A1 ARP100103389A ARP100103389A AR080662A1 AR 080662 A1 AR080662 A1 AR 080662A1 AR P100103389 A ARP100103389 A AR P100103389A AR P100103389 A ARP100103389 A AR P100103389A AR 080662 A1 AR080662 A1 AR 080662A1
Authority
AR
Argentina
Prior art keywords
solid oral
oral dose
dose form
same
formulation process
Prior art date
Application number
ARP100103389A
Other languages
English (en)
Inventor
Deepak Bahl
Danny Yu
Kieran James Crowley
Original Assignee
Rp Scherer Technologies Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rp Scherer Technologies Llc filed Critical Rp Scherer Technologies Llc
Publication of AR080662A1 publication Critical patent/AR080662A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5169—Proteins, e.g. albumin, gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Reivindicacion 1: Un método para preparar una forma de dosis solida oral que contenga nanopartículas, con un proceso que incluya los siguientes pasos: (a) la reduccion del tamano de la partícula de al menos un ingrediente activo farmacéuticamente disperso en una solucion que contenga gelatina de pescado para formar una nanosuspension; y (b) el secado por congelacion de la nanosuspension del punto (a) para obtener una forma de dosis solida oral.
ARP100103389A 2009-09-16 2010-09-16 Forma de dosis oral solida con contenido de nanoparticulas y proceso de formulacion de la misma utilizando gelatina de pescado AR080662A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US12/560,813 US9775819B2 (en) 2009-09-16 2009-09-16 Oral solid dosage form containing nanoparticles and process of formulating the same using fish gelatin

Publications (1)

Publication Number Publication Date
AR080662A1 true AR080662A1 (es) 2012-05-02

Family

ID=43730820

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP100103389A AR080662A1 (es) 2009-09-16 2010-09-16 Forma de dosis oral solida con contenido de nanoparticulas y proceso de formulacion de la misma utilizando gelatina de pescado

Country Status (14)

Country Link
US (1) US9775819B2 (es)
EP (1) EP2477608B1 (es)
JP (1) JP5707405B2 (es)
KR (1) KR101714688B1 (es)
CN (1) CN102686218B (es)
AR (1) AR080662A1 (es)
AU (1) AU2010295781B2 (es)
BR (1) BR112012005969A2 (es)
CA (1) CA2774210C (es)
DK (1) DK2477608T3 (es)
ES (1) ES2527225T3 (es)
IL (1) IL218598A (es)
MX (2) MX2012003204A (es)
WO (1) WO2011034809A1 (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8853260B2 (en) * 1997-06-27 2014-10-07 Abraxis Bioscience, Llc Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
US20030199425A1 (en) * 1997-06-27 2003-10-23 Desai Neil P. Compositions and methods for treatment of hyperplasia
LT2481402T (lt) * 2007-03-07 2018-10-25 Abraxis Bioscience, Llc Nanodalelė, apimanti rapamiciną ir albuminą, kaip priešvėžinį agentą
US20100166869A1 (en) * 2007-05-03 2010-07-01 Desai Neil P Methods and compositions for treating pulmonary hypertension
AU2008260447B2 (en) * 2007-06-01 2013-10-10 Abraxis Bioscience, Llc Methods and compositions for treating recurrent cancer
US10548839B2 (en) 2010-03-16 2020-02-04 Wei Tian Process of manufacturing a lyophilized fast dissolving, multi-phasic dosage form
CN102406941B (zh) * 2011-07-29 2015-03-11 沈阳药科大学 含有改性明胶肽的纳米化难溶性活性组分及其制备方法
BR112014027352B1 (pt) * 2012-05-02 2022-10-25 New Market Pharmaceuticals Composições farmacêuticas para a introdução sistêmica direta
DE102012221900A1 (de) 2012-11-29 2014-06-05 2LUTION GmbH Feste Lösungen von Coffein
US10166197B2 (en) 2015-02-13 2019-01-01 St. John's University Sugar ester nanoparticle stabilizers
SG10202107367SA (en) 2016-12-31 2021-08-30 Bioxcel Therapeutics Inc Use of sublingual dexmedetomidine for the treatment of agitation
EP3403725A1 (de) * 2017-05-15 2018-11-21 Eppendorf AG Pipettierhilfssystem
KR102105872B1 (ko) * 2018-05-18 2020-04-29 강원대학교산학협력단 열용융압출법을 이용하여 제조된 구리 나노콜로이드 분산체 및 이의 용도
KR102105829B1 (ko) * 2018-05-18 2020-04-29 강원대학교산학협력단 열용융압출법을 이용하여 제조된 산화아연 나노콜로이드 분산체 및 이의 용도
KR102105827B1 (ko) * 2018-05-18 2020-04-29 강원대학교산학협력단 열용융압출법을 이용하여 제조된 셀레늄 나노콜로이드 분산체 및 이의 용도
KR102104257B1 (ko) * 2018-05-18 2020-04-24 강원대학교산학협력단 열용융압출법을 이용하여 제조된 망간 나노콜로이드 분산체 및 이의 용도
ES3004544T3 (en) 2018-06-27 2025-03-12 Bioxcel Therapeutics Inc Film formulations containing dexmedetomidine and methods of producing them
US11523988B2 (en) 2018-11-29 2022-12-13 Catalent U.K. Swindon Zydis Limited Oral dispersible vaccine comprising virosomes
US20240024288A1 (en) 2019-07-19 2024-01-25 Bioxcel Therapeutics, Inc. Non-sedating dexmedetomidine treatment regimens
EP3804702A1 (de) 2019-10-10 2021-04-14 Bayer AG Verfahren zur herstellung einer pharmazeutischen formulierung mit wirkstoff, polymer und tensid
EP4243796A4 (en) 2020-11-16 2025-01-22 Orcosa Inc. IMPROVED USE OF CANNABINOIDS IN THE TREATMENT OF EPILEPSY
US11672761B2 (en) 2020-11-16 2023-06-13 Orcosa Inc. Rapidly infusing platform and compositions for therapeutic treatment in humans
WO2022216769A1 (en) * 2021-04-07 2022-10-13 Fontana Biosciences, Inc. Rapidly disintegrating allyl isothiocyanate tablet
US11806334B1 (en) 2023-01-12 2023-11-07 Bioxcel Therapeutics, Inc. Non-sedating dexmedetomidine treatment regimens

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2792702B2 (ja) * 1988-10-05 1998-09-03 ネクスター・フアーマシユーテイカルズ・インコーポレイテツド 乾燥時に改善された安定性を示すリポソームの調製方法
US5145684A (en) * 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
CA2125282C (en) * 1991-12-05 1999-08-31 Jens-Christian Wunderlich Pharmaceutically applicable nanosol and process for preparing the same
US5302401A (en) * 1992-12-09 1994-04-12 Sterling Winthrop Inc. Method to reduce particle size growth during lyophilization
US6066337A (en) * 1994-01-27 2000-05-23 The Board Of Regents Of The University Of Oklahoma And Janssen Pharmaceutica, Inc. Method for producing a rapidly dissolving dosage form
US5510118A (en) * 1995-02-14 1996-04-23 Nanosystems Llc Process for preparing therapeutic compositions containing nanoparticles
DE19637517A1 (de) 1996-09-13 1998-03-19 Basf Ag Herstellung von pulverförmigen, kaltwasserdispergierbaren Carotinoid-Zubereitungen und die Verwendung der neuen Carotinoid-Zubereitungen
GB9802088D0 (en) 1998-01-30 1998-03-25 Scherer Ltd R P Pharmaceutical products
DE19856432A1 (de) 1998-12-08 2000-06-15 Basf Ag Nanopartikuläre Kern-Schale Systeme sowie deren Verwendung in pharmazeutischen und kosmetischen Zubereitungen
GB9908014D0 (en) * 1999-04-08 1999-06-02 Scherer Corp R P Pharmaceutical compositions
JP2003524624A (ja) 1999-04-09 2003-08-19 ジェシー エル エス オウ 治療薬の組織への送達を高める方法及び組成物
US6316029B1 (en) * 2000-05-18 2001-11-13 Flak Pharma International, Ltd. Rapidly disintegrating solid oral dosage form
US7105176B2 (en) * 2000-11-29 2006-09-12 Basf Aktiengesellschaft Production of solid preparations of water-soluble, sparingly water-soluble or water-insoluble active compounds
FR2825293B1 (fr) * 2001-06-05 2004-05-07 Coletica Particules solides insolubles dans l'eau traitees, preparation et utilisation
US6509040B1 (en) * 2001-06-22 2003-01-21 R.P. Scherer Corporation Fast dispersing dosage forms essentially free of mammalian gelatin
US7713551B2 (en) * 2002-09-11 2010-05-11 Elan Pharma International Ltd. Gel stabilized nanoparticulate active agent compositions
JP4776233B2 (ja) 2002-11-12 2011-09-21 エラン ファーマ インターナショナル，リミティド 摩損しにくくかつプルランを含む速崩壊性固形製剤
DE10253111A1 (de) * 2002-11-13 2004-05-27 Basf Ag Pulverförmige Phytosterol-Formulierungen
JP2008506780A (ja) 2004-07-19 2008-03-06 セレーター ファーマスーティカルズ、インク． 活性剤放出のための粒子状構築物
US8268791B2 (en) * 2004-08-25 2012-09-18 Aegis Therapeutics, Llc. Alkylglycoside compositions for drug administration
US7592429B2 (en) 2005-05-03 2009-09-22 Ucb Sa Sclerostin-binding antibody
KR20080047509A (ko) 2005-05-23 2008-05-29 엘란 파마 인터내셔널 리미티드 혈소판 응집 억제제를 함유하는 나노입자형 조절 방출조성물
DE102005030952A1 (de) * 2005-06-30 2007-01-18 Basf Ag Verfahren zur Herstellung einer wässrigen Suspension und einer pulverförmigen Zubereitung eines oder mehrerer Carotinoide
DE102005031468A1 (de) * 2005-07-04 2007-01-18 Basf Ag Wässrige Suspensionen schwer wasserlöslicher oder wasserunlöslicher Wirkstoffe und daraus hergestellte Trockenpulver
WO2008137831A1 (en) 2007-05-07 2008-11-13 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Water-soluble nanoparticles containing water-insoluble compounds
GB0714223D0 (en) 2007-07-20 2007-08-29 Fujifilm Mfg Europe Bv Preparation of fine particles
CN103784408A (zh) * 2007-07-24 2014-05-14 安迅生物制药公司 用于制备微粒的技术
US20100055246A1 (en) * 2008-08-28 2010-03-04 Dong June Ahn Nutrition delivery capsules for functional foods

Also Published As

Publication number Publication date
BR112012005969A2 (pt) 2017-06-06
ES2527225T3 (es) 2015-01-21
EP2477608A4 (en) 2013-03-06
US9775819B2 (en) 2017-10-03
CA2774210C (en) 2017-08-29
EP2477608B1 (en) 2014-10-29
KR20120089815A (ko) 2012-08-13
CA2774210A1 (en) 2011-03-24
DK2477608T3 (en) 2015-01-19
US20110064812A1 (en) 2011-03-17
CN102686218B (zh) 2017-12-19
HK1175984A1 (en) 2013-07-19
AU2010295781A1 (en) 2012-04-19
EP2477608A1 (en) 2012-07-25
IL218598A0 (en) 2012-05-31
KR101714688B1 (ko) 2017-03-09
MX2012003204A (es) 2012-05-29
JP2013505243A (ja) 2013-02-14
AU2010295781B2 (en) 2015-07-09
MX349106B (es) 2017-07-12
JP5707405B2 (ja) 2015-04-30
IL218598A (en) 2015-09-24
CN102686218A (zh) 2012-09-19
WO2011034809A1 (en) 2011-03-24

Similar Documents

Publication Publication Date Title
MX2012003204A (es) Forma de dosificacion solida oral que contiene nanoparticulas y proceso para su formulacion utilizando gelatina de pescado.
PE20211069A1 (es) Composicion que comprende 5'-metilselenoadenosina, selenoadenosil-l-homocisteina y gama glutamil-metilselenocisteina
EA201400972A1 (ru) Лекарственные формы немедленного высвобождения с защитой от несанкционированного применения
CL2018002914A1 (es) Formas de dosificación de liberación modificada disuasivas de abuso.
SV2016005236A (es) Formulación compuesta para administración oral que comprende ezetimibe y rosuvastatina
BR112012023324B8 (pt) processo de preparação de uma forma de dosagem multifásica liofilizada de dissolução rápida
AR083208A1 (es) Uso de estearato de magnesio en formulaciones de polvo seco para inhalacion
CL2016001874A1 (es) Forma de dosificación oral sólida de liberación modificada que comprende pridopidina y un excipiente de control de velocidad; formulación farmacéutica que comprende a la forma de dosificación; uso de la forma de dosificación o de la formulación farmacéutica para tratar una enfermedad neurodegenerativa o relacionada con dopamina, como la enfermedad de huntington, entre otras.
CO6321225A2 (es) Particulas portadoras sólidas para mejorar la procesabilidad de un agente farmacéutico
PE20080765A1 (es) Formas de dosificacion farmaceutica
MX2019007956A (es) Liberacion autorregulada de ingrediente farmaceutico activo.
AR100519A1 (es) Envase tipo cápsula de gelatina blanda y su método de fabricación
AR093012A1 (es) Composiciones farmaceuticas en polvo, activas, con enmascaramiento del sabor y procesos para su fabricacion
DOP2012000217A (es) Pastillas de gelatina blanda con nicotina
MX2016010179A (es) Composiciones de donepezilo y métodos para tratar la enfermedad de alzheimer.
MX2022009231A (es) Inhalador de polvo seco y metodo de uso.
AR095159A2 (es) Una composición farmacéutica en forma de cápsula para administración oral
AR061351A1 (es) Composicion de carbamato de bencimidazol
AR075180A1 (es) Formulaciones orales solidas de una pirido-pirimidinona
AR102778A1 (es) Composición farmacéutica, su preparación y sus usos
MX375187B (es) Composiciones farmacéuticas secas que comprenden nanopartículas de agente activo ligadas a partículas portadoras.
UY35890A (es) Uso de laquinimod para retrasar la progresión de la enfermedad de huntington
CL2016000182A1 (es) Composición farmacéutica anti-tuberculosis estable en una forma de un comprimido recubierto que comprende gránulos de isoniazid y gránulos de rifapentina y su proceso de preparación
CL2011001207A1 (es) Extruidos que contienen al menos una sustancia farmacéuticamente activa en forma de agujas, tal que la relación entre el tamaño de partículas de la sustancia farmacéuticamente activa con forma de agujas y el diámetro de la cadena es de al menos 1:20; composición farmacéutica; y su uso para preparar medicamentos.
MX2018008517A (es) Composicion y metodo para tratar la enfermedad de chagas.

Legal Events

Date Code Title Description
FC Refusal